Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia
Anemia is a common and important complication in patients with chronic kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis stimulating agents (ESAs) and iron. Hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors (HIF-PHIs) have been developed to t...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2023-08-01
|
| Series: | Kidney Diseases |
| Online Access: | https://beta.karger.com/Article/FullText/533304 |
| _version_ | 1797690721240612864 |
|---|---|
| author | Xue Wang Cuiting Wei Delong Zhao Xuefeng Sun Fengge Zhu Yan Mei Qian Ma Guangyan Cai Xiangmei Chen Ping Li |
| author_facet | Xue Wang Cuiting Wei Delong Zhao Xuefeng Sun Fengge Zhu Yan Mei Qian Ma Guangyan Cai Xiangmei Chen Ping Li |
| author_sort | Xue Wang |
| collection | DOAJ |
| description | Anemia is a common and important complication in patients with chronic kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis stimulating agents (ESAs) and iron. Hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors (HIF-PHIs) have been developed to treat renal anemia through a novel mechanism. HIF-PHIs increase EPO at physiologic blood concentrations and also improve the supply of hematopoietic iron. Iron is the main component of hemoglobin, and ensuring efficient iron metabolism is essential in the treatment of anemia. HIF-PHIs may have advantages in improving iron utilization and mobilization compared to ESAs. Most HIF-PHIs trials revealed a significant decline of hepcidin, increase transferrin level and total iron binding capacity in patients. From a clinical point of view, improvements in iron metabolism should translate into a reduction in the need for iron supplementation, although timely and comparative assessment of iron supplementation across studies are complicated due to the large variability in the iron regimen employed. This review summarizes the mechanism of HIF-PHIs on improved iron metabolism and the route of iron usage in the trials for dialysis-dependent CKD and non-dialysis CKD. And this review also makes an interpretation of the clinical practice guidelines in China and recommendation by Asia Pacific Society of Nephrology. |
| first_indexed | 2024-03-12T02:03:12Z |
| format | Article |
| id | doaj.art-6cb4c7e9ac264d56b11b3dee57476d2a |
| institution | Directory Open Access Journal |
| issn | 2296-9357 |
| language | English |
| last_indexed | 2024-03-12T02:03:12Z |
| publishDate | 2023-08-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Kidney Diseases |
| spelling | doaj.art-6cb4c7e9ac264d56b11b3dee57476d2a2023-09-07T07:56:39ZengKarger PublishersKidney Diseases2296-93572023-08-0110.1159/000533304533304Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemiaXue WangCuiting WeiDelong ZhaoXuefeng SunFengge ZhuYan MeiQian MaGuangyan CaiXiangmei ChenPing LiAnemia is a common and important complication in patients with chronic kidney disease (CKD). Accordingly, the current treatment is based on erythropoiesis stimulating agents (ESAs) and iron. Hypoxia-inducible factor (HIF) prolyl hydroxylase domain (PHD) inhibitors (HIF-PHIs) have been developed to treat renal anemia through a novel mechanism. HIF-PHIs increase EPO at physiologic blood concentrations and also improve the supply of hematopoietic iron. Iron is the main component of hemoglobin, and ensuring efficient iron metabolism is essential in the treatment of anemia. HIF-PHIs may have advantages in improving iron utilization and mobilization compared to ESAs. Most HIF-PHIs trials revealed a significant decline of hepcidin, increase transferrin level and total iron binding capacity in patients. From a clinical point of view, improvements in iron metabolism should translate into a reduction in the need for iron supplementation, although timely and comparative assessment of iron supplementation across studies are complicated due to the large variability in the iron regimen employed. This review summarizes the mechanism of HIF-PHIs on improved iron metabolism and the route of iron usage in the trials for dialysis-dependent CKD and non-dialysis CKD. And this review also makes an interpretation of the clinical practice guidelines in China and recommendation by Asia Pacific Society of Nephrology.https://beta.karger.com/Article/FullText/533304 |
| spellingShingle | Xue Wang Cuiting Wei Delong Zhao Xuefeng Sun Fengge Zhu Yan Mei Qian Ma Guangyan Cai Xiangmei Chen Ping Li Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia Kidney Diseases |
| title | Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia |
| title_full | Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia |
| title_fullStr | Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia |
| title_full_unstemmed | Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia |
| title_short | Iron supplements concomitant with HIF-PHIs in the treatment of CKD anemia |
| title_sort | iron supplements concomitant with hif phis in the treatment of ckd anemia |
| url | https://beta.karger.com/Article/FullText/533304 |
| work_keys_str_mv | AT xuewang ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT cuitingwei ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT delongzhao ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT xuefengsun ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT fenggezhu ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT yanmei ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT qianma ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT guangyancai ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT xiangmeichen ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia AT pingli ironsupplementsconcomitantwithhifphisinthetreatmentofckdanemia |